Praziquantel (antischistosomal drug): is it clastogenic, co-clastogenic or anticlastogenic?
- 1 March 1994
- journal article
- Published by Elsevier in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
- Vol. 305 (2) , 165-173
- https://doi.org/10.1016/0027-5107(94)90236-4
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Reduction in chromosomal damage in schistosomiasis patients after treatment with praziquantelMutation Research/Genetic Toxicology, 1993
- Enhancement of benzene clastogenicity by praziquantel in miceMutation Research/Genetic Toxicology, 1989
- Effect of dimethyl sulfoxide on the genotoxicity and metabolism of benzene in vivoCarcinogenesis: Integrative Cancer Research, 1989
- Measurement of micronuclei in lymphocytesMutation Research/Environmental Mutagenesis and Related Subjects, 1985
- Prooxidant States and Tumor PromotionScience, 1985
- trans, trans-Muconic acid, an open-chain urinary metabolite of benzene in mice. Quantification by high-pressure liquid chromatographyXenobiotica, 1985
- Urothelial Hyperplasia and Neoplasia: A Response to Chronic Urinary Tract Infections in RatsJournal of Urology, 1984
- PraziquantelMedicinal Research Reviews, 1983
- Absence of mutagenicity of praziquantel, a new, effective, anti-schistosomal drug, in bacteria, yeasts, insects and mammalian cellsMutation Research/Genetic Toxicology, 1978
- Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen testsMutation Research/Environmental Mutagenesis and Related Subjects, 1975